Palpable marker composition

Patent metadata

Field	Value
Publication number	US-11058780-B2
Application number	US-201716302517-A
Country	US
Kind code	B2
Filing date	May 19, 2017
Priority date	May 20, 2016
Publication date	Jul 13, 2021
Grant date	Jul 13, 2021

Abstract

The present invention relates to a palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 50,000 centipoise (cP) after administration, for use for identifying and/or locating a non palpable tumor. In one embodiment the composition the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body. In another embodiment the composition is a liquid before administration and has the ability to transform into a crystalline or amorphous solid after administration.

First claim

The invention claimed is:

1. A palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of saccharides with at least one pyranose or furanose saccharide unit, sucrose, lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least one pyranose or furanose saccharide unit, or trisaccharides, or tetrasaccharides, or mixtures thereof, wherein the palpable marker composition comprises lactose octaisobutyrate (LOIB), and wherein the composition is a liquid before administration into the human or animal body, and:
a) increases in viscosity by more than 50,000 centipoise (cP) after administration, for using the palpable marker composition for marking, identifying and/or locating a target tissue; or
b) becomes a semi-crystaline, crystaline or amorphous solid after administration for using the palpable marker composition for marking, identifying and/or locating a target tissue.

2. The palpable marker composition according to claim 1 , wherein the non-water soluble carbohydrates are selected from the group consisting of sucrose, lactose, maltose, trehalose, raffinose and derivatives of disaccharides with at least one pyranose unit.

3. The palpable marker composition according to claim 1 , wherein the target tissue is selected from the group consisting of a non-palpable tumor, a palpable tumor, and a target needing to be surgically removed or destroyed.

4. The palpable marker composition according to claim 1 , wherein the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body.

5. The palpable marker composition according to claim 1 , wherein the composition is a liquid before administration and has the ability to transform into a gel-like material after administration into the human or animal body due to diffusion of a molecule out of the administered material and into surrounding tissue.

6. The palpable marker composition according to claim 1 , wherein the composition becomes a semi-crystalline, crystalline or amorphous solid by precipitation after administration into the human or animal body due to diffusion of a molecule out of the administered material and into surrounding tissue.

7. The palpable marker composition according to claim 1 , wherein the increase in viscosity or precipitation after administration into the human or animal body is due to diffusion of solvent molecules out of the administered material and into the surrounding tissue.

8. The palpable marker composition according to claim 1 , wherein the non-water soluble carbohydrates are disaccharides with structures selected from:

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 in formulae I, II and III are selected collectively from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are independently selected from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl;
or wherein all groups of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are selected collectively from the group consisting of acetyl, isobutyryl or propionyl; or wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are independently selected from the group consisting acetyl, isobutyryl or propionyl;
and wherein both pure anomers and mixtures of α- and β-anomers of the above mentioned structural variations are claimed.

9. The palpable marker composition according to claim 1 , wherein the non-water soluble carbohydrates are trisaccharides with structures selected from:

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 in formulae IV are selected collectively from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are independently selected from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl;
or wherein all groups of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are selected collectively from the group consisting of acetyl, isobutyryl or propionyl; or wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are independently selected from the group consisting acetyl, isobutyryl or propionyl;
and wherein both pure anomers and mixtures of α- and β-anomers of the above mentioned structural variations are claimed.

10. The palpable marker composition according to claim 1 wherein at least 50% of the non-water soluble carbohydrates are mono- or oligosaccharides containing at least one amino sugar unit.

11. The palpable marker composition according to claim 10 , wherein the amino sugar has the structure:

wherein R 1 , R 2 , R 3 , R 4 and R 5 in formulae V are selected collectively from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl, and mono-, di-, tri- or tetra-saccharide derivatives;
or wherein all groups of R 1 , R 2 , R 3 , R 4 and R 5 are selected collectively from the group consisting of acetyl, isobutyryl or propionyl; or wherein R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting acetyl, isobutyryl or propionyl;
and wherein both pure anomers and mixtures of anomers such as α- and β-anomer centres of the above mentioned structural variations are claimed.

12. The palpable marker composition according to claim 1 , wherein the composition comprises contrast agents that make the composition visible by PET imaging, SPECT imaging, Ultrasound imaging, x-ray imaging, fluorescence imaging, or OCT imaging.

13. The palpable marker composition according to claim 1 , which is administered to the human or animal body through a syringe, an endoscope, a bronchoscope or a biopsy equipment to the target tissue.

14. The palpable marker composition according to claim 1 for local administration, wherein at least 60% of an administrated amount of marker remains more than 24 hours within 10 cm from an injection point when the palpable marker composition is administrated to a human or animal body.

15. A method for identifying and/or locating a non-palpable tumor or a target tissue needing to be surgically removed or destroyed, the method comprising injection of a palpable marker composition, wherein

Assignees

• Univ Denmark Tech Dtu
• Nanovi Radiotherapy Aps

Inventors

• Andresen Thomas Lars
• Irming Jølck Rasmus
• Bruun Linda Maria

Classifications

• A61K2123/00

  Preparations for testing in vivo · CPC title

• A61K51/1213

  Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature · CPC title

• A61K51/0491 Primary

  Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers · CPC title

• A61K49/226

  Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels · CPC title

• A61K49/0073

  semi-solid, gel, hydrogel, ointment · CPC title